ASH Clinical News in Search of Associate Editors for 2023-2025 Term
Quality of Life in Long-Term Survivors of HCT Similar to General Population
Mikkael Sekeres, MD, David Steensma, MD, and Aaron Gerds, MD
On July 8, 2022, our managing editor for ASH Clinical News, Kristin Hubing, left this earth at a devastatingly young age for what we hope is a more joyous place. She left behind her husband Kyle and her infant son Theo, along with scores of family, friends, and her work family at ASH. Her death leaves a huge hole in all our hearts.
Most Read Articles
- AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation
- High-Precision, Allogeneic Cell Therapy Improves Survival in Patients With Hematologic Malignancies
- Venetoclax Combination Therapy Works Better in Some AML Subtypes Than Others
- SRSF2 Mutation Status May Predict Romiplostim Treatment Response in Lower-Risk MDS
- Nilotinib Demonstrates Greater Efficacy Than Imatinib in CML
Dr. Gerds shares his thoughts on the August issue including the relevance of the feature story on marijuana, the link between lenalidomide and the risk of therapy-related myeloid neoplasms, and more.
A study published in Journal of Clinical Oncology found that such patients’ antibody binding and neutralization against the original SARS-CoV-2 virus and variants such as Delta and Omicron were substantially lower compared to healthy vaccinees.
“Our result might offer a personalized approach to reducing the risk of t-MNs,” said study researcher Koichi Takahashi, MD, PhD, of the University of Texas MD Anderson Cancer Center.